-
International Journal of Chronic Obstructive Pulmonary Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
Original Research
(1506) Views (789) Full article downloads
Authors: Heike Rau-Berger, Harald Mitfessel, Thomas Glaab
Published Date October 2010
Volume 2010:5 Pages 367 - 373
DOI: http://dx.doi.org/10.2147/COPD.S14082
Heike Rau-Berger1, Harald Mitfessel2, Thomas Glaab11Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim; 2Pulmonology Practice, Remscheid, Germany
Aim: This observational study with tiotropium Respimat® was performed in a real-life setting to investigate its effectiveness with regard to physical functioning and tolerability.
Methods: Patients with chronic obstructive pulmonary disease (COPD; n = 1,230; mean age, 65.5 years) received tiotropium 5 µg once daily via Respimat® Soft Inhaler for 6 weeks in an open-label observational study. At baseline and week 6, patients completed the Physical Function subdomain [PF-10] of the Short Form (SF) 36 questionnaire.
Results: Improvement in standardized PF-10 score of ≥10 points was achieved by 61.5% of patients. Mean (SD) standardized PF-10 scores improved by 13.4 (15.9) points, from 49.0 (24.5) to 62.3 points (23.5; P < 0.001). Results in smokers (n = 435) were not significantly different to those in nonsmokers. The general condition of patients improved during treatment. Adverse events were reported by 4.0% of patients and were chiefly respiratory symptoms and dry mouth.
Conclusion: In COPD patients receiving tiotropium Respimat® in daily practice, physical function improved rapidly within 6 weeks of treatment, irrespective of smoking status.
Keywords: COPD, tiotropium, physical function, therapy
Readers of this article also read:
COPD is frequent in conditions of comorbidity in patients treated with various diseases in a university hospital
Direct costs of chronic obstructive pulmonary disease among managed care patients
Budesonide/formoterol combination in COPD: a US perspective
Development and implementation of treadmill exercise testing protocols in COPD
Improving adherence with inhaler therapy in COPD
Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients
In search of parsimony: reliability and validity of the Functional Performance Inventory-Short Form
Association between lung function and exacerbation frequency in patients with COPD
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




